The generic copies will be supplied in 90 countries, subject to regulatory approvals there, the statement said.
Indian drugmaker Cipla will make the injections in India and has plans to manufacture in South Africa, which is trying to grow its drugs manufacturing industry to meet the continent's needs and reduce dependency on imports that was exposed by the COVID-19 pandemic. Pre-exposure prophylaxis is an effective way for an at-risk HIV-negative person to reduce the risk of infection. But until recently, PrEP was only available in pill form. GSK's product is the first non-pill option.
Yup? Yep!
um, why is it a thing to send the generics to Africa and Asia and Latin America and elsewhere? seems messed up and makes me question the purity of generic drugs.